The protocol described here uses F1 ES cells to study cis-regulation of gene expression in monoallelic enhancer deleted cells generated using CRISPR/Cas9 genome editing (Figure 1). The gRNA and allele-specific primer design for genotyping and gene expression are the key factors in this approach. Each allele-specific primer set must be validated by qPCR to confirm allele specificity. Allele-specific primers that amplify only their respective genomic DNA target are ideal (Figure 2). Ideally these primers have a SNP at their 3' end. Primers with less allele-specificity can be used if they display a minimum of a 5 Ct value difference in their amplification of the correct vs. the incorrect genotype25. Primers that carry a SNP more 5' than the 4th base from the 3' end usually fail to exhibit allele specificity and amplify both genotypes with equal efficiency, revealing the importance of the SNP position in the primer34. In addition a purine/purine or pyrimidine/pyrimidine substitution has been shown to have a greater impact on the Tm difference of two primers compared to a purine/pyrimidine substitution25.
Primary screening of a 96-well plate of DNA isolated from ES cell clones is conducted with allele-specific inside primers to identify clones that carry a deletion on one or both alleles. These deleted clones are further screened with outside allele-specific primers to confirm each deletion. The example given here is from an efficient gRNA pair that resulted in 46% of clones carrying a deletion on the 129, Cast, or both alleles (Figure 3). Secondary screening is done for confirmed monoallelic deletion clones to identify indels around the gRNA target sites on the non-deleted allele as the frequency of indel occurrence at the gRNA target site is high23. Indels around the gRNA are not identifiable in the primary screening, as these clones show no deletion with inside primers and do not amplify with the outside primers (Figure 4). Monoallelic deletion clones that give amplification with both sets of left and right gRNA flanking primers have their other allele largely intact as they do not contain a deletion larger than the 5' or 3' gRNA flanking amplicons. Sequencing the amplicons from the gRNA flanking primers will identify indels smaller than the gRNA flanking amplicons which may not be noticeable in the qPCR. The monoallelic deletion clones that do not give amplification at both regions in the secondary screening are not included for further gene expression analysis. As gRNA target regions are chosen outside the region suspected to have enhancer function, indels smaller than the gRNA flanking amplicons are not likely to affect enhancer function and clones containing these can be included in further analysis.
To restrict a large deletion to one allele a gRNA can be chosen which overlaps a SNP in the seed region or the PAM. Described here is an example of a high-efficiency deletion (53%) on the 129 allele due to a SNP in the PAM for the 3' gRNA on the Cast allele (Figure 5). This deletion removed the SCR, a recently described Sox2 specific enhancer in ES cells18,22. Although the introduction of the large deletion was greatly reduced on the Cast allele, three clones (1, 11, 75) were identified with a large deletion on the Cast allele (Figure 5). Of these three clones two (1, 11) contained 3' break points within 50 bp of the 3' gRNA target region. For the third clone we were not able to identify the 3' break point and concluded that the deletion was greater than 11 kb18. Deletions with one or both of their break points located >100 bp from either the 5' of 3' gRNA target region are difficult to genotype, generally account for 15-30% of all clones, and remain uncharacterized in the primary screening as the deletion is not amplified with the outside primers.
Once clones with monoallelic deletion have been identified they are analyzed for allele-specific gene expression using absolute quantification by reverse transcription qPCR. Gene expression from clones carrying a monoallelic deletion of the critical Sox2 enhancer region, the SCR, is shown here compared with expression in wild-type F1 ES cells (Figure 6). Specifically, clones carrying a deletion of the enhancer region on the 129 allele displayed a decrease in 129 transcript levels whereas clones carrying a deletion on the Cast allele displayed a decrease in Cast transcript levels. The allele-specific gene expression analysis revealed that this distal enhancer region, SCR, is a critical cis-regulator of Sox2 in ES cells18.

Figure 2. Testing the allele-specificity of 129 and Cast allele-specific primers. (A) Amplification from primers for the 129 genotype. (B) Amplification from primers for the Cast genotype. In both A and B the lines display the amplification profiles for C57BL/6 genomic DNA which has the same genotype as 129 DNA at these specific SNPs; the lines with open circles display the amplification profiles for Cast genomic DNA. Amplification resulting from the primer set with the most allele-specificity is shown in green (Allele-specific primer-1), a primer set displaying a 5 Ct difference is shown in purple (Allele-specific primer-2) and a primer set displaying a minimal difference in Ct value is represented in red (Allele-specific primer-3, primer details in Table 7). The red primer set would not be appropriate for allele-specific screening. RFU denotes relative fluorescence units. Please click here to view a larger version of this figure.

Figure 3. Results obtained after screening a 96-well plate with allele-specific inside and outside primers. (A) qPCR results from the screen with inside primers (Enh_del_IS_F1_129, Enh_del _IS_F1C, Enh_del _IS_R1) B) qPCR results from the screen with outside primers (Enh_del_OS_F1, Enh del_OS_R1_129, Enh_del_OS_F2C, Enh_del_OS_R3, primer details in Table 7). In both grey bars represent amplification from Cast-specific primers and black bars represent amplification from 129-specific primers. Note that only clones with a deletion on one or both alleles are screened with the outside primers. The relative amplification of each allele was calculated using 2-CT to approximate the initial concentration and subsequently expressing each allele as a percentage of the sum of the two alleles. Please click here to view a larger version of this figure.

Figure 4. Clones with a monoallelic deletion are screened to identify large indels at the gRNA target sites. Primers flanking the gRNA target regions are used to confirm that the non-deleted allele is intact. Only monoallelic clones without large indels at the target sites on the non-deleted allele are used in the subsequent expression analysis. Please click here to view a larger version of this figure.

Figure 5. Clones obtained from the Sox2 SCR deletion. Shown are the qPCR results from a screen with inside primers (pr111R, pr111F_129, pr111F_Cast, details in Table 7). Grey bars represent amplification from Cast-specific primers and black bars represent amplification from 129-specific primers. Note that the deletion is heavily skewed towards the 129 allele due to the presence of a SNP in the PAM of the 3' gRNA target region on the Cast allele. The relative amplification of each allele was calculated using 2-CT to approximate the initial concentration and subsequently expressing each allele as a percentage of the sum of the two alleles. Please click here to view a larger version of this figure.

Figure 6. SCR deletion dramatically reduces the expression of Sox2. Representative results from 129 or Cast SCR deleted clones. Red bars represent expression of the Sox2 Cast allele and blue bar represents amplification of the Sox2 129 allele. Deletion of the SCR on the 129 allele reduced expression of Sox2 (129) whereas deletion of the SCR on the Cast allele reduced expression of Sox2 (Cast). Data displayed are an average of three technical replicates, error bars not shown. Primers used for Sox2 expression analysis [Sox2_F, Sox2(129)_R, Sox2(Cast)_R] are listed in Table 7. Please click here to view a larger version of this figure.
| Reagent | Stock concentration | Volume | Final concentration |
| GlutaMAX | 200 mM | 6 ml | 2 mM |
| 2-Mercaptoethanol | 10 mM | 6 ml | 0.1 mM |
| MEM Non-essential aminoacids (NEAA) | 10 mM | 6 ml | 0.1 mM |
| Sodium Pyruvate | 100 mM | 6 ml | 1 mM |
| Pencillin/Streptomycin | 10,000 units | 3 ml | 50 U/ml |
| FBS | | 90 ml | 15% |
| CHIR99021* | 10 mM | | 3 µM |
| PD0325901* | 10 mM | | 1 µM |
| LIF* | 107 units/ml | | 1000 U/ml |
|
| # to prepare ES cell media, add the above components to 500 ml of high glucose DMEM. The ES cell media should not be stored for more than 4 weeks and with inhibitors* not more than 2 weeks. |
Table 1. ES cell media.
| Reagent | Stock concentration | Volume | Final concentration |
| GlutaMAX | 200 mM | 5 ml | 2 mM |
| Pencillin/Streptomycin | 10,000 units | 5 ml | 100 U/ml |
| FBS | | 50 ml | 10% |
|
| # to prepare Spin media, add the above components to 500 ml of high glucose DMEM. |
Table 2. Spin media.
| Reagent | Final concentration | Volume (50 ml) |
| 1x PBS without Ca/Mg2+ | | 42.0 ml |
| BSA Fraction V (7.5 %) | 15% (v/v) | 7.5 ml |
| 0.5 M EDTA | 5 mM | 0.5 ml |
Table 3. Collection buffer.
| Reagent | Final concentration | Volume (50 ml) |
| 1x HBSS | | 47.25 ml |
| 1M HEPES | 25 mM | 1.25 ml |
| 0.5 M EDTA | 5 mM | 0.5 ml |
| BSA Fraction V (7.5 %) | 1% (v/v) | 0.5 ml |
| FBS | 1% (v/v) | 0.5 ml |
Table 4. Sorting buffer.
Table 5. Recovery media.
| ES cell media | 60% |
| FBS | 20% |
| DMSO | 20% |
Table 6. 2x freezing media.


Table 7. List of primers.